Brown Rudnick Represents Lupin in $880 million acquisition
PUBLISHED ON: 07/24/2015
RELATED EXPERIENCESHOW MORE
Brown Rudnick represents Lupin Limited, a transnational pharmaceutical company based in Mumbai, in connection with Lupin's agreement to acquire privately held GAVIS Pharmaceuticals LLC and Novel Laboratories Inc. (GAVIS), subject to certain closing conditions, in a transaction valued at $880 million. Commenting on the acquisition, Ms. Vinita Gupta, Chief Executive Officer of Lupin Limited, said, "This is a pivotal acquisition for Lupin as it aligns with our goal to expand and deepen our US presence." The Brown Rudnick team is led by Corporate Partners Rob Funsten and Katy Gardner and includes Finance Partner Mary Bucci and Corporate Associates Steve Cheng, Mary Ambacher, Sarah Wilk and Andrew Oliver. Support for the transactions has been provided by Partner Vince Guglielmotti, Counsel Barbara Kelly, and Associate James Maynor (Tax), Partners Doug Cohen and Associates Kyle Johnson and Jeff Vigliotti (Environmental/Real Estate) and Partner Mark Leonardo (Trademarks).
To learn more about this deal, please read the following press releases: